Table 6. Sensitivity of QFT-GIT calculated over the total of patients tested (indeterminate results included as negative results) and only over the interpretable results (indeterminate results excluded) in PTB patients stratified by HIV status according to smear microscopy status.

	Indeterminate results included as negative results			Indeterminate results excluded
	AFB-positive	AFB-negative	P (AFB- negative versus AFB -positive)	AFB-positive	AFB-negative	P (AFB- negative versus AFB -positive)
	Positive over total % (95% CI)
HIV-infected	12/19	14/19		12/12	14/17
	63.2 (38.4–83.4)	73.7 (48.8–90.9	0.7281	100.0 (73.5–100)	82.4 (56.6–96.2)	0.2463
HIV-uninfected	43/46	10/12		43/44	10/12
	93.5 (82.1–98.6)	83.3 (51.6–97.9)	0.2735	97.7 (88.0–99.9)	83.3 (51.6–97.9)	0.1127
Total	55/65	24/31		55/56	24/29
	84.6 (73.5–92.4)	77.4 (58.8–90.4)	0.4031	98.2 (90.5–99.9)	82.8 (64.2–94.2)	0.0163

Footnotes: QFT-GIT: QuantiFERON® Gold in Tube; TB: Tuberculosis; HIV: Human Immunodeficiency Virus, AFB: Acid Fast Bacilli.